MX2024005852A - Compuestos para tratar anemias asociadas a mds y otras afecciones. - Google Patents

Compuestos para tratar anemias asociadas a mds y otras afecciones.

Info

Publication number
MX2024005852A
MX2024005852A MX2024005852A MX2024005852A MX2024005852A MX 2024005852 A MX2024005852 A MX 2024005852A MX 2024005852 A MX2024005852 A MX 2024005852A MX 2024005852 A MX2024005852 A MX 2024005852A MX 2024005852 A MX2024005852 A MX 2024005852A
Authority
MX
Mexico
Prior art keywords
conditions
anemias
compounds
treating mds
mds
Prior art date
Application number
MX2024005852A
Other languages
English (en)
Spanish (es)
Inventor
Charles Kung
Vanessa Beynon
Suman Joy Bhatia
Lenny Dang
Melissa L Dibacco
Varsha V Iyer
Megan Lynch
Ophelia Qiping Yin
Rolandas Urbstonaitis
Zhen Xiao
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2024005852A publication Critical patent/MX2024005852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2024005852A 2021-11-16 2022-11-15 Compuestos para tratar anemias asociadas a mds y otras afecciones. MX2024005852A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US202263357240P 2022-06-30 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (1)

Publication Number Publication Date
MX2024005852A true MX2024005852A (es) 2024-05-28

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005852A MX2024005852A (es) 2021-11-16 2022-11-15 Compuestos para tratar anemias asociadas a mds y otras afecciones.

Country Status (11)

Country Link
US (1) US20250108049A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543345A (cg-RX-API-DMAC7.html)
KR (1) KR20240107326A (cg-RX-API-DMAC7.html)
AU (1) AU2022390088B2 (cg-RX-API-DMAC7.html)
CA (1) CA3236880A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001431A1 (cg-RX-API-DMAC7.html)
IL (1) IL312679A (cg-RX-API-DMAC7.html)
MX (1) MX2024005852A (cg-RX-API-DMAC7.html)
TW (1) TW202329935A (cg-RX-API-DMAC7.html)
WO (1) WO2023091414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238659A1 (en) * 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
JP2022533227A (ja) 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ, インコーポレイテッド N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態

Also Published As

Publication number Publication date
AU2022390088B2 (en) 2026-07-02
WO2023091414A1 (en) 2023-05-25
AU2022390088A1 (en) 2024-05-09
KR20240107326A (ko) 2024-07-09
CA3236880A1 (en) 2023-05-25
CL2024001431A1 (es) 2024-10-25
JP2024543345A (ja) 2024-11-21
US20250108049A1 (en) 2025-04-03
EP4433057A1 (en) 2024-09-25
IL312679A (en) 2024-07-01
TW202329935A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
PH12020551464A1 (en) Cd73 inhibitors
PH12022551424A1 (en) Kras g12c inhibitors.
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2023010411A (es) Inhibidores de erbb/btk.
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
ZA202207667B (en) Sulfonimidamide compounds as nlrp3 modulators
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
MX2023010909A (es) Derivados de purina como agentes anticancerigenos.
PH12022550812A1 (en) Diacylglycerol acyltransferase 2 inhibitor
PH12022550175A1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
MX2024003475A (es) Polimorfos como inhibidores de erbb.
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
CL2024001431A1 (es) Compuestos para tratar anemias asociadas a mds y otras afecciones
PH12022551282A1 (en) Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
EP4670791A3 (en) Compounds and compositions for treating conditions associated with lpa receptor activity